https://www.selleckchem.com/pr....oducts/sovleplenib-h
32; 95% confidence interval [CI], 0.12-0.86; P=0.026). Secondary outcomes, including stroke, mortality, and delirium, were similar between subjects randomised to dexmedetomidine (16/54 [30%] or saline control (22 [41%]; odds ratio=0.61 [95% CI, 0.28-1.36]). The incidence of bradycardia and hypotension was similar between groups (14/54 (26%) vs. 17/54 (32%) (odds ratio0.76 (95%CI0.33-1.76) and 29/54 (54%) vs. 36/54 (67%) (odds ratio0.58 (95%CI0.27-1.26), respectively). The length of hospital stay was shorter in the dexmedeto
Like
Comment
Share
